CROSBY Research – SinoMab BioScience (3681 HK/ NR): An innovative immunology specialist

2 Jun 2025

Based in Hong Kong, SinoMab is a pioneering biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of therapeutics for immunological diseases, with a primary focus on monoclonal antibody (mAb)-based biologics. Since its inception, SinoMab has cultivated a diverse pipeline of complementary mAb-based biologics and innovative chemical entities (NCEs), addressing a broad spectrum of immunological conditions. Committed to meeting critical unmet medical needs, the company strategically targets key autoimmune pathological mechanisms, including T cells, B cells, and complementary pathways.